JP2009508471A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009508471A5 JP2009508471A5 JP2008525285A JP2008525285A JP2009508471A5 JP 2009508471 A5 JP2009508471 A5 JP 2009508471A5 JP 2008525285 A JP2008525285 A JP 2008525285A JP 2008525285 A JP2008525285 A JP 2008525285A JP 2009508471 A5 JP2009508471 A5 JP 2009508471A5
- Authority
- JP
- Japan
- Prior art keywords
- tissue
- cell
- amino acid
- isolated polypeptide
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001519 tissues Anatomy 0.000 claims 28
- 229920001184 polypeptide Polymers 0.000 claims 21
- 210000004027 cells Anatomy 0.000 claims 20
- 125000000539 amino acid group Chemical group 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 108010011901 glutaminyl-glutamyl-glutaminyl-leucyl-glutamyl-arginyl-alanyl-leucyl-asparagyl-seryl-serine Proteins 0.000 claims 3
- 210000000056 organs Anatomy 0.000 claims 3
- 210000000988 Bone and Bones Anatomy 0.000 claims 2
- 210000002889 Endothelial Cells Anatomy 0.000 claims 2
- 210000001428 Peripheral Nervous System Anatomy 0.000 claims 2
- 230000001120 cytoprotect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 230000002633 protecting Effects 0.000 claims 2
- 210000001218 Blood-Brain Barrier Anatomy 0.000 claims 1
- 210000001759 Blood-Nerve Barrier Anatomy 0.000 claims 1
- 210000002937 Blood-Testis Barrier Anatomy 0.000 claims 1
- 208000003432 Bone Disease Diseases 0.000 claims 1
- 210000001736 Capillaries Anatomy 0.000 claims 1
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 1
- 210000003169 Central Nervous System Anatomy 0.000 claims 1
- 206010057668 Cognitive disease Diseases 0.000 claims 1
- 210000002808 Connective Tissue Anatomy 0.000 claims 1
- 201000006306 Cor pulmonale Diseases 0.000 claims 1
- 210000000981 Epithelium Anatomy 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 210000001508 Eye Anatomy 0.000 claims 1
- 208000008665 Gastrointestinal Disease Diseases 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 208000001083 Kidney Disease Diseases 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- 210000004400 Mucous Membrane Anatomy 0.000 claims 1
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 206010038683 Respiratory disease Diseases 0.000 claims 1
- 208000006641 Skin Disease Diseases 0.000 claims 1
- 210000004927 Skin cells Anatomy 0.000 claims 1
- 210000001550 Testis Anatomy 0.000 claims 1
- 210000000515 Tooth Anatomy 0.000 claims 1
- 208000000207 Urologic Disease Diseases 0.000 claims 1
- 210000001789 adipocyte Anatomy 0.000 claims 1
- 230000001919 adrenal Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 210000003890 endocrine cells Anatomy 0.000 claims 1
- 230000002357 endometrial Effects 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 210000002919 epithelial cells Anatomy 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 201000002146 gastrointestinal system disease Diseases 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 claims 1
- 210000002064 heart cell Anatomy 0.000 claims 1
- 230000002209 hydrophobic Effects 0.000 claims 1
- 230000000968 intestinal Effects 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002503 metabolic Effects 0.000 claims 1
- 210000000663 muscle cells Anatomy 0.000 claims 1
- 210000003867 nerve cell Anatomy 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 210000002569 neurons Anatomy 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000001932 reproductive system disease Diseases 0.000 claims 1
- 230000002207 retinal Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000005728 strengthening Methods 0.000 claims 1
- 230000004083 survival Effects 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
Claims (26)
- 30以下のアミノ酸残基からなり、エリスロポエチンのヘリックスBの11個の外向アミノ酸残基を含み、前記アミノ酸残基のうちの1つが、保存的又は非保存的置換で任意に置換されている、単離ポリペプチド、又はそのレトロ-インバーソ-類似体。
- H1-N1-(L)n-P1-H2(式中、nは0〜1であり、かつH1及びH2は同一又は異なる疎水性アミノ酸であり、N1は負荷電アミノ酸であり、L1は極性アミノ酸であり、かつP1は正荷電アミノ酸である。)のアミノ酸モチーフを含む、請求項1記載の単離ポリペプチド。
- アミノ酸配列QEQLERALNSS(配列番号:40)を含み、前記アミノ酸残基の1つが、保存的又は非保存的置換で任意に置換されている、請求項1記載の単離ポリペプチド、又はそのレトロ-インバーソ-類似体。
- アミノ酸配列QEQLERALNSS(配列番号:40)からなり、前記アミノ酸残基の1つが、保存的又は非保存的置換で任意に置換されている、請求項3記載の単離ポリペプチド、又はそのレトロ-インバーソ-類似体。
- アミノ酸配列QEQLERALNSS(配列番号:40)からなる、請求項3記載の単離ポリペプチド、又はそのレトロ-インバーソ-類似体。
- 請求項1〜5のいずれか1項記載の単離ポリペプチドのレトロ-インバーソ-類似体。
- アミノ酸配列QEQLERALNSSLRRYINMLTRTR(配列番号:41)を含み、前記アミノ酸残基の1つが、保存的又は非保存的置換で任意に置換されている、請求項1記載の単離ポリペプチド。
- アミノ酸配列CSLNENIQEQLERALNSS(配列番号:43)を含み、前記アミノ酸残基の1つが、保存的又は非保存的置換で任意に置換されている、請求項1記載の単離ポリペプチド。
- アミノ酸又はアミノ酸同等物による保存的又は非保存的置換を含む、請求項1〜4、6又は7のいずれかに記載の単離ポリペプチド。
- 前記ポリペプチドが、ポリエチレングリコールの付加により修飾されている、請求項1〜9のいずれかに記載の単離ポリペプチド。
- 受容者においてヘモグロビンを増加させない、請求項1〜10のいずれかに記載の単離ポリペプチド。
- 神経細胞又は組織、骨細胞又は組織、眼細胞又は組織、脂肪細胞又は組織、結合細胞又は組織、髪細胞又は組織、歯細胞又は組織、粘膜細胞又は組織、膵臓細胞又は組織、内分泌細胞又は組織、耳細胞又は組織、上皮細胞又は組織、皮膚細胞又は組織、筋細胞又は組織、心臓細胞又は組織、肺細胞又は組織、肝臓細胞又は組織、腎臓細胞又は組織、腸細胞又は組織、副腎細胞又は組織、毛管細胞又は組織、内皮細胞又は組織、精巣細胞又は組織、卵巣細胞又は組織、あるいは子宮内膜細胞又は組織などの応答性細胞、組織又は器官の、又は幹細胞の、機能及び/又は生存率を保護、維持、強化あるいは回復させることなどの細胞保護活性を有する、請求項1〜10のいずれかに記載の単離ポリペプチド。
- 中枢神経系組織、末梢神経系組織、心臓組織、又は網膜組織などの興奮性組織において細胞保護活性を有する、請求項1〜10のいずれかに記載の単離ポリペプチド。
- 血液脳関門、血液-眼関門、血液-精巣関門、血液-卵巣関門、血液-神経関門、及び血液-脊髄関門などの内皮細胞障壁を横断できる、請求項1〜10のいずれかに記載の単離ポリペプチド。
- 請求項1〜10のいずれかに記載の単離ポリペプチド、及び、医薬として許容し得る担体を含む、医薬組成物。
- 経口投与、鼻腔内投与、眼球投与、吸入投与、経皮投与、直腸投与、舌下投与、又は非経口投与用に製剤されている、請求項15記載の医薬組成物。
- 灌流液として製剤されている、請求項15記載の医薬組成物。
- 哺乳動物の身体から単離した応答性細胞、組織又は器官の生存率を保護、維持又は高めるための方法であって、前記細胞、組織又は器官を請求項1〜10のいずれか1項記載の単離ポリペプチド又は請求項15〜17のいずれか1項記載の医薬組成物に曝すことを含む、前記方法。
- 前記哺乳動物の身体がヒトの身体である、請求項18記載の方法。
- その必要がある対象の、心血管系疾患、心肺疾患、呼吸疾患、腎疾患、泌尿器系疾患、生殖器系疾患、骨疾患、皮膚疾患、胃腸疾患、内分泌異常、代謝異常、認知機能障害、又は中枢神経系若しくは末梢神経系の疾患若しくは障害の予防、治療的処置又は予防的処置用の医薬組成物の製造のための、請求項1〜10のいずれか1項記載の単離ポリペプチドの使用。
- 前記対象がヒトである、請求項20記載の使用。
- 請求項1〜10のいずれか1項記載の単離ポリペプチドをコードするヌクレオチド配列を含む、単離核酸。
- 請求項22記載の核酸を含むベクター。
- 発現ベクターである、請求項23記載のベクター。
- 請求項24記載の発現ベクターを含む宿主細胞。
- 単離ポリペプチドを組換え的に製造する方法であって、a)前記ポリペプチドの発現に適切な条件下で、請求項25記載の宿主細胞を培地中で培養すること、及びb)前記培地から前記ポリペプチドを回収及び単離することを含む、前記方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70574105P | 2005-08-05 | 2005-08-05 | |
US60/705,741 | 2005-08-05 | ||
US70627605P | 2005-08-08 | 2005-08-08 | |
US60/706,276 | 2005-08-08 | ||
US83173706P | 2006-07-18 | 2006-07-18 | |
US60/831,737 | 2006-07-18 | ||
PCT/US2006/031061 WO2007019545A2 (en) | 2005-08-05 | 2006-08-07 | Tissue protective peptides and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013027479A Division JP5918155B2 (ja) | 2005-08-05 | 2013-02-15 | 組織保護ペプチド及びその使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009508471A JP2009508471A (ja) | 2009-03-05 |
JP2009508471A5 true JP2009508471A5 (ja) | 2011-05-19 |
JP5274253B2 JP5274253B2 (ja) | 2013-08-28 |
Family
ID=37728020
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008525285A Expired - Fee Related JP5274253B2 (ja) | 2005-08-05 | 2006-08-07 | 組織保護ペプチド及びその使用 |
JP2013027479A Expired - Fee Related JP5918155B2 (ja) | 2005-08-05 | 2013-02-15 | 組織保護ペプチド及びその使用 |
JP2015020020A Expired - Fee Related JP6158235B2 (ja) | 2005-08-05 | 2015-02-04 | 組織保護ペプチド及びその使用 |
JP2016114010A Expired - Fee Related JP6491621B2 (ja) | 2005-08-05 | 2016-06-08 | 組織保護ペプチド及びその使用 |
JP2018071318A Pending JP2018134084A (ja) | 2005-08-05 | 2018-04-03 | 組織保護ペプチド及びその使用 |
JP2020013151A Pending JP2020078317A (ja) | 2005-08-05 | 2020-01-30 | 組織保護ペプチド及びその使用 |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013027479A Expired - Fee Related JP5918155B2 (ja) | 2005-08-05 | 2013-02-15 | 組織保護ペプチド及びその使用 |
JP2015020020A Expired - Fee Related JP6158235B2 (ja) | 2005-08-05 | 2015-02-04 | 組織保護ペプチド及びその使用 |
JP2016114010A Expired - Fee Related JP6491621B2 (ja) | 2005-08-05 | 2016-06-08 | 組織保護ペプチド及びその使用 |
JP2018071318A Pending JP2018134084A (ja) | 2005-08-05 | 2018-04-03 | 組織保護ペプチド及びその使用 |
JP2020013151A Pending JP2020078317A (ja) | 2005-08-05 | 2020-01-30 | 組織保護ペプチド及びその使用 |
Country Status (26)
Country | Link |
---|---|
US (7) | US8071554B2 (ja) |
EP (5) | EP2594279B1 (ja) |
JP (6) | JP5274253B2 (ja) |
KR (7) | KR20190084136A (ja) |
CN (2) | CN103724418B (ja) |
AU (1) | AU2006278264B2 (ja) |
BR (1) | BRPI0614529A8 (ja) |
CA (3) | CA2618396C (ja) |
DK (3) | DK2371855T3 (ja) |
EA (1) | EA015672B1 (ja) |
ES (3) | ES2653864T3 (ja) |
HK (1) | HK1127751A1 (ja) |
HU (3) | HUE026444T2 (ja) |
IL (3) | IL189287A (ja) |
IN (1) | IN2014CN02050A (ja) |
LT (2) | LT2540309T (ja) |
MX (3) | MX2008001509A (ja) |
NO (1) | NO20081112L (ja) |
NZ (1) | NZ565937A (ja) |
PL (3) | PL2540309T3 (ja) |
PT (3) | PT2540309T (ja) |
SG (2) | SG10201805825SA (ja) |
SI (3) | SI2540309T1 (ja) |
UA (1) | UA100222C2 (ja) |
WO (1) | WO2007019545A2 (ja) |
ZA (1) | ZA201101890B (ja) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
US9345745B2 (en) | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
US9585932B2 (en) * | 2005-04-29 | 2017-03-07 | Peter C. Dowling | Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders |
WO2007052154A2 (en) | 2005-04-29 | 2007-05-10 | University Of Medicine And Dentistry Of New Jersey | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
PT2540309T (pt) | 2005-08-05 | 2017-12-29 | Araim Pharmaceuticals Inc | Péptidos protectores de tecidos e suas utilizações |
MX2008015392A (es) * | 2006-06-07 | 2009-05-05 | Univ Tokushima | Tratamiento de enfermedades isquemicas que usan eritropoyetina. |
WO2008058942A2 (en) * | 2006-11-13 | 2008-05-22 | Charite - Universitätsmedezin Berlin | Method of cell culture and method of treatment comprising a vepo protein variant |
AU2014203195B2 (en) * | 2008-01-22 | 2016-03-31 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
AU2016203452B2 (en) * | 2008-01-22 | 2018-02-22 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
SG188161A1 (en) * | 2008-01-22 | 2013-03-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
WO2012051581A2 (en) * | 2010-10-14 | 2012-04-19 | Rutgers, The State University Of New Jersey | Intestinal peptide targeting ligands |
US9566349B2 (en) * | 2010-10-14 | 2017-02-14 | Rutgers, The State University Of New Jersey | Intestinal peptide targeting ligands |
CN102180948A (zh) * | 2011-03-03 | 2011-09-14 | 复旦大学附属中山医院 | 一种具有肾脏保护作用的短肽及其制备方法和应用 |
CN102212111B (zh) * | 2011-05-05 | 2014-04-30 | 中国人民解放军第三军医大学 | 小分子多肽和小分子多肽脂质体及其运用 |
US20140178335A1 (en) * | 2011-07-27 | 2014-06-26 | Neumedicines, Inc. | Use of il-12 to generate endogenous erythropoietin |
WO2013042118A1 (en) * | 2011-09-20 | 2013-03-28 | A.A. Cash Technology Ltd | Methods and devices for occluding blood flow to an organ |
KR101148191B1 (ko) * | 2011-09-27 | 2012-05-23 | 김후정 | 에리스로포이에틴-유래 펩타이드 및 그 용도 |
WO2013158871A1 (en) | 2012-04-20 | 2013-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of erythropoietin and derivatives for treating hypertension |
WO2015009820A2 (en) * | 2013-07-17 | 2015-01-22 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
CN104744593A (zh) * | 2013-12-25 | 2015-07-01 | 深圳先进技术研究院 | 一种抗肿瘤血管生成免疫复合肽及其制备方法和应用 |
US9622483B2 (en) | 2014-02-19 | 2017-04-18 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
US11039621B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
US11039620B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
KR20150130616A (ko) * | 2014-05-13 | 2015-11-24 | (주)케어젠 | 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도 |
CN105837663A (zh) * | 2014-06-22 | 2016-08-10 | 马恒标 | 组织保护活性多肽sl10及其应用 |
CN108347916B (zh) | 2015-10-14 | 2022-02-08 | 先时迈纳米生物科技股份有限公司 | 一种减少冰晶形成的组合物及其方法 |
JP2019523633A (ja) | 2016-04-29 | 2019-08-29 | アライム ファーマシューティカルズ,インコーポレーテッド | 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド |
PL3538065T3 (pl) | 2016-11-10 | 2023-12-04 | Asc Regenity Ltd. | Formulacje kosmetyczne do zastosowań miejscowych zawierające cząsteczki pochodzące z erytropoetyny |
WO2018155997A1 (ko) * | 2017-02-27 | 2018-08-30 | 재단법인 대구경북과학기술원 | 에리스로포이에틴 유래 펩티드의 세포손상방지에 효과를 통한 활용 |
CN108503690B (zh) * | 2017-02-28 | 2020-07-03 | 暨南大学 | 一种促进创伤后组织修复与再生的修复肽及其应用 |
WO2018157773A1 (zh) | 2017-02-28 | 2018-09-07 | 暨南大学 | 一种促进创伤后组织修复与再生的修复肽及其应用 |
WO2019199661A1 (en) * | 2018-04-08 | 2019-10-17 | Brim Biotechnology, Inc. | Application of pedf-derived short peptides in tendon healing |
KR102300060B1 (ko) | 2018-06-12 | 2021-09-08 | 주식회사 엘지에너지솔루션 | 2열 터미널 구조의 pcb 다이렉트 커넥터 |
AU2019337564A1 (en) | 2018-09-10 | 2021-05-06 | Cold Spring Harbor Laboratory | Methods for treating pancreatitis |
CN112390877B (zh) * | 2019-08-16 | 2022-10-04 | 董红燕 | Pedf衍生多肽组合物及其在制备保护肺损伤药物中的应用 |
CN118255845A (zh) * | 2022-12-27 | 2024-06-28 | 上海瑞吉康生物医药有限公司 | 相分离逆转多肽的变体及其应用 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
US4558006A (en) * | 1983-02-04 | 1985-12-10 | Kirin-Amgen, Inc. | A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin |
US5051448A (en) | 1984-07-24 | 1991-09-24 | The Mclean Hospital Corporation | GABA esters and GABA analog esters |
US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
US4798824A (en) | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
US5498694A (en) | 1989-05-25 | 1996-03-12 | La Jolla Cancer Research Foundation | Peptides of the cytoplasmic domain of integrin |
DE3924746A1 (de) * | 1989-07-26 | 1991-01-31 | Behringwerke Ag | Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper |
CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
US6140120A (en) * | 1993-02-12 | 2000-10-31 | Board Of Trustees Of Leland Stanford Jr. University | Regulated transcription of targeted genes and other biological events |
US5559103A (en) | 1993-07-21 | 1996-09-24 | Cytel Corporation | Bivalent sialyl X saccharides |
US5571787A (en) | 1993-07-30 | 1996-11-05 | Myelos Corporation | Prosaposin as a neurotrophic factor |
US5700909A (en) * | 1993-07-30 | 1997-12-23 | The Regents Of The University Of California | Prosaposin and cytokine-derived peptides |
WO1995021919A2 (en) * | 1994-02-14 | 1995-08-17 | Kirin Brewery Company, Limited | Protein having tpo activity |
ITFI940106A1 (it) * | 1994-05-27 | 1995-11-27 | Menarini Ricerche Sud Spa | Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica |
US5576423A (en) | 1994-12-02 | 1996-11-19 | Schering Corporation | Antibodies to the slam protein expressed on activated T cells |
HUP9901069A2 (hu) * | 1995-06-07 | 1999-07-28 | Affymax Technologies, N.V. | Az eritropoietin receptorhoz kötődő vegyületek és peptidek |
JP2001524944A (ja) * | 1997-03-05 | 2001-12-04 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 神経障害性疼痛の緩和方法 |
US7270809B2 (en) * | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
US7153943B2 (en) * | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
NZ514690A (en) * | 1999-04-13 | 2004-07-30 | Kenneth S | Modulation of excitable tissue function by peripherally administered erythropoietin |
WO2001083548A1 (fr) * | 2000-04-28 | 2001-11-08 | Effector Cell Institute | Nouveau derive de facteur chimiotactique cellulaire |
ES2361824T3 (es) * | 2000-12-20 | 2011-06-22 | F. Hoffmann-La Roche Ag | Conjugados de eritropoyetina (epo) con polietilenglicol (peg). |
PA8536201A1 (es) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
CA2437272A1 (en) * | 2001-02-06 | 2002-08-15 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Modified erythropoietin (epo) with reduced immunogenicity |
WO2002085940A2 (en) * | 2001-04-04 | 2002-10-31 | Genodyssee | New polynucleotides and polypeptides of the erythropoietin gene |
KR100467751B1 (ko) * | 2001-12-03 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
US7300915B2 (en) * | 2002-06-05 | 2007-11-27 | The Regents Of The University Of California | Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain |
PL374580A1 (en) | 2002-07-01 | 2005-10-31 | The Kenneth S.Warren Institute, Inc. | Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
KR100478455B1 (ko) | 2002-08-19 | 2005-03-22 | 삼성전자주식회사 | 전자렌지 |
AU2003273297A1 (en) | 2002-09-09 | 2004-03-29 | Kenneth S. Warren Institute, Inc. | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
WO2005025606A1 (en) | 2003-09-09 | 2005-03-24 | Warren Pharmaceuticals, Inc. | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
CA2500715A1 (en) * | 2002-10-03 | 2004-04-15 | Epimmune, Inc. | Hla binding peptides and their uses |
JP2004305006A (ja) * | 2003-04-01 | 2004-11-04 | Japan Science & Technology Agency | 人工調製肺サーファクタント |
CN1812800B (zh) * | 2003-04-25 | 2013-01-16 | 匹兹堡大学 | 用于促进和增强神经修复和再生的肌肉来源的细胞(mdc) |
US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
US7645733B2 (en) | 2003-09-29 | 2010-01-12 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions |
US7842661B2 (en) | 2003-11-24 | 2010-11-30 | Novo Nordisk A/S | Glycopegylated erythropoietin formulations |
US20080227696A1 (en) * | 2005-02-22 | 2008-09-18 | Biosurface Engineering Technologies, Inc. | Single branch heparin-binding growth factor analogs |
WO2007010552A2 (en) | 2005-03-17 | 2007-01-25 | Serum Institute Of India Limited | N- terminal peg conjugate of erythropoietin |
WO2007052154A2 (en) | 2005-04-29 | 2007-05-10 | University Of Medicine And Dentistry Of New Jersey | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
US9345745B2 (en) | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
US8329652B2 (en) | 2005-05-10 | 2012-12-11 | Neoloch Aps | Neuritogenic peptides |
EP1736481A1 (en) | 2005-05-13 | 2006-12-27 | Charite Universitätsmedizin-Berlin | Erythropoietin variants |
PT2540309T (pt) | 2005-08-05 | 2017-12-29 | Araim Pharmaceuticals Inc | Péptidos protectores de tecidos e suas utilizações |
EP2960341B1 (en) | 2007-11-29 | 2018-06-27 | Molecular Health GmbH | Novel tissue protective erythropoietin receptor (nepor) and methods of use |
SG188161A1 (en) | 2008-01-22 | 2013-03-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
CA2725601A1 (en) * | 2008-04-28 | 2009-11-05 | President And Fellows Of Harvard College | Supercharged proteins for cell penetration |
WO2011022056A2 (en) | 2009-08-18 | 2011-02-24 | Medical College Of Georgia Research Institute, Inc. | PEPTIDE MODULATORS OF THE δPKC INTERACTION WITH THE D SUBUNIT OF F1FO ATP SYNTHASE/ATPASE AND USES THEREOF |
-
2006
- 2006-08-07 PT PT121753529T patent/PT2540309T/pt unknown
- 2006-08-07 WO PCT/US2006/031061 patent/WO2007019545A2/en active Application Filing
- 2006-08-07 ES ES12175352.9T patent/ES2653864T3/es active Active
- 2006-08-07 US US11/997,898 patent/US8071554B2/en not_active Expired - Fee Related
- 2006-08-07 KR KR1020197019568A patent/KR20190084136A/ko not_active Application Discontinuation
- 2006-08-07 PL PL12175352T patent/PL2540309T3/pl unknown
- 2006-08-07 KR KR1020187030050A patent/KR20180116475A/ko not_active Application Discontinuation
- 2006-08-07 UA UAA200802850A patent/UA100222C2/uk unknown
- 2006-08-07 CN CN201310529242.5A patent/CN103724418B/zh not_active Expired - Fee Related
- 2006-08-07 LT LTEP12175352.9T patent/LT2540309T/lt unknown
- 2006-08-07 PT PT121753669T patent/PT2594279T/pt unknown
- 2006-08-07 SI SI200632233T patent/SI2540309T1/en unknown
- 2006-08-07 HU HUE11163194A patent/HUE026444T2/en unknown
- 2006-08-07 IN IN2050CHN2014 patent/IN2014CN02050A/en unknown
- 2006-08-07 CA CA2618396A patent/CA2618396C/en not_active Expired - Fee Related
- 2006-08-07 KR KR1020207016998A patent/KR20200072568A/ko not_active Application Discontinuation
- 2006-08-07 PT PT111631941T patent/PT2371855E/pt unknown
- 2006-08-07 SI SI200632230T patent/SI2594279T1/en unknown
- 2006-08-07 ES ES11163194.1T patent/ES2550055T3/es active Active
- 2006-08-07 BR BRPI0614529A patent/BRPI0614529A8/pt not_active Application Discontinuation
- 2006-08-07 KR KR1020087005373A patent/KR101626153B1/ko active IP Right Grant
- 2006-08-07 DK DK11163194.1T patent/DK2371855T3/en active
- 2006-08-07 NZ NZ565937A patent/NZ565937A/en not_active IP Right Cessation
- 2006-08-07 ES ES12175366.9T patent/ES2653790T3/es active Active
- 2006-08-07 EA EA200800536A patent/EA015672B1/ru not_active IP Right Cessation
- 2006-08-07 EP EP12175366.9A patent/EP2594279B1/en active Active
- 2006-08-07 PL PL12175366T patent/PL2594279T3/pl unknown
- 2006-08-07 EP EP17202352.5A patent/EP3363451A1/en not_active Withdrawn
- 2006-08-07 MX MX2008001509A patent/MX2008001509A/es active IP Right Grant
- 2006-08-07 MX MX2014011168A patent/MX339613B/es unknown
- 2006-08-07 KR KR1020177005579A patent/KR20170027868A/ko active Search and Examination
- 2006-08-07 LT LTEP12175366.9T patent/LT2594279T/lt unknown
- 2006-08-07 EP EP11163194.1A patent/EP2371855B1/en active Active
- 2006-08-07 CA CA2982909A patent/CA2982909A1/en not_active Abandoned
- 2006-08-07 PL PL11163194T patent/PL2371855T3/pl unknown
- 2006-08-07 SG SG10201805825SA patent/SG10201805825SA/en unknown
- 2006-08-07 JP JP2008525285A patent/JP5274253B2/ja not_active Expired - Fee Related
- 2006-08-07 CA CA3079319A patent/CA3079319A1/en not_active Abandoned
- 2006-08-07 CN CN2006800348244A patent/CN101378772B/zh not_active Expired - Fee Related
- 2006-08-07 KR KR1020137016015A patent/KR101713368B1/ko active IP Right Grant
- 2006-08-07 KR KR1020187016750A patent/KR20180067735A/ko not_active Application Discontinuation
- 2006-08-07 MX MX2016004825A patent/MX364100B/es unknown
- 2006-08-07 EP EP06801051A patent/EP1924276A4/en not_active Withdrawn
- 2006-08-07 AU AU2006278264A patent/AU2006278264B2/en not_active Ceased
- 2006-08-07 HU HUE12175352A patent/HUE035793T2/en unknown
- 2006-08-07 SG SG2014007868A patent/SG2014007868A/en unknown
- 2006-08-07 SI SI200631979T patent/SI2371855T1/sl unknown
- 2006-08-07 HU HUE12175366A patent/HUE035655T2/en unknown
- 2006-08-07 DK DK12175352.9T patent/DK2540309T3/en active
- 2006-08-07 DK DK12175366.9T patent/DK2594279T3/en active
- 2006-08-07 EP EP12175352.9A patent/EP2540309B1/en active Active
-
2008
- 2008-02-05 IL IL189287A patent/IL189287A/en active IP Right Grant
- 2008-03-03 NO NO20081112A patent/NO20081112L/no not_active Application Discontinuation
-
2009
- 2009-08-21 HK HK09107682.9A patent/HK1127751A1/xx not_active IP Right Cessation
-
2011
- 2011-03-11 ZA ZA2011/01890A patent/ZA201101890B/en unknown
- 2011-10-20 US US13/278,131 patent/US8716245B2/en not_active Expired - Fee Related
-
2012
- 2012-04-16 US US13/448,345 patent/US8673861B2/en not_active Expired - Fee Related
-
2013
- 2013-02-15 JP JP2013027479A patent/JP5918155B2/ja not_active Expired - Fee Related
-
2014
- 2014-04-08 US US14/248,030 patent/US9340598B2/en not_active Expired - Fee Related
-
2015
- 2015-02-04 JP JP2015020020A patent/JP6158235B2/ja not_active Expired - Fee Related
- 2015-02-10 US US14/618,873 patent/US20150152156A1/en not_active Abandoned
- 2015-06-29 IL IL239695A patent/IL239695A0/en active IP Right Grant
-
2016
- 2016-05-05 US US15/147,848 patent/US10100096B2/en not_active Expired - Fee Related
- 2016-06-08 JP JP2016114010A patent/JP6491621B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-03 JP JP2018071318A patent/JP2018134084A/ja active Pending
- 2018-08-23 IL IL261346A patent/IL261346A/en unknown
- 2018-09-25 US US16/141,724 patent/US20190016769A1/en not_active Abandoned
-
2020
- 2020-01-30 JP JP2020013151A patent/JP2020078317A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009508471A5 (ja) | ||
JP2013126995A5 (ja) | ||
US20210269506A1 (en) | Polynucleotides encoding immune modulating polypeptides | |
JP7285220B2 (ja) | 連結したインターロイキン-12(il12)ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子 | |
CN110382695A (zh) | 通过crispr/cpf1介导的基因编辑来预防肌营养不良 | |
JP6948250B2 (ja) | Larファミリーホスファターゼの活性を阻害する組成物及び方法 | |
SI2594279T1 (en) | Tissue protective peptides and their uses | |
WO2006071778A3 (en) | Treatment of parkinson's disease and related disorders using postpartum derived cells | |
US20170173128A1 (en) | Targeted adaptive vaccines | |
US20160194368A1 (en) | Circular polynucleotides | |
CN106659803A (zh) | 核酸疫苗 | |
WO2005077333A3 (en) | Gel-based delivery of recombinant adeno-associated virus vectors | |
JPH09504177A (ja) | Pth活性を有する化合物およびこれをコードする組み換えdnaベクター | |
HU229282B1 (en) | Hiv vaccine compositions | |
JP6757024B2 (ja) | 視覚機能再生剤又は視覚機能低下予防剤 | |
BRPI0415563A (pt) | método para o tratamento do mal de parkinson, uso de um vetor viral, vetor de expressão viral, composição farmacêutica, célula hospedeira isolada, linhagem de células de empacotamento, mamìfero não humano quimérico, dispositivo de cultura celular implantável, cápsula biocompatìvel, método para tratamento de uma doença do sistema nervoso, célula de mamìfero, e, método para produzir neurturin ou um seu equivalente funcional | |
JPH04503073A (ja) | アナフィラトキシン受容体リガンド | |
TW200824705A (en) | Reconstituted surfactants having improved properties | |
JP2009507474A5 (ja) | ||
JP2020508668A (ja) | ミオミキサーにより促進される筋細胞融合に関連する組成物および方法 | |
JPWO2020071519A1 (ja) | 間葉系幹細胞の動員に基づく疾患治療薬 | |
JP2008502323A5 (ja) | ||
Wang | MSCs transplantation may be a potential therapeutic strategy for COVID-19 treatment | |
JP2016514672A (ja) | 抗原およびアジュバントとしてのインターロイキン−23を有するワクチン | |
JP2007505159A5 (ja) |